Managing HIV Drug Resistance

The Latest

CDC Study Reinforces the Importance of Annual STI Testing Among MSM

Rectal and throat tests matter too, and providers should be recommending them.

By Sony Salzman

Antiviral Stewardship Program Reduces Medication Errors at a Veterans Affairs Hospital

When people living with HIV are admitted to a hospital, they may not be able to bring their medications with them, and could be prescribed new medication by a doctor who doesn't understand their complete medical history.

By Sony Salzman

This Week in HIV Research: Additional Nuance on Pregnancy and Antiretrovirals

Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Exorcizing Our PrEP Demons

Experts push for normalization of PrEP; U.S. HIV transmission rates across the care continuum; sociodemographic disadvantage and HIV drug resistance; real-world success of integrase inhibitors for treatment-experienced people.

By Myles Helfand

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

By Simon Collins for HIV i-Base

Exploring HIV Drug Resistance in Trans Women, MSM

We spoke with a mentor/mentee pair, an infectious diseases expert and a second-year medical student, about a research project that focuses on HIV drug resistance in trans women and MSM.

By Jeanine Barone

New Study Triggers Concerns Over Use of Molecular HIV Surveillance

This study identified some information about transgender women's sexual networks in Los Angeles. But activists worry about privacy and the potential that the surveillance method will be used in HIV criminalization cases.

By Martha Kempner

What Is the State of the Art in HIV Treatment and Prevention?

With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.

By Sony Salzman

ART Resistance Spreads: A Top HIV Clinical Development of 2017

With expansion of the use of antimicrobial agents comes the inevitable expansion of microbial drug resistance -- and so it is with antiretrovirals. In a 2017 World Health Organization (WHO) report on surveillance for pre-treatment antiretroviral drug...

By David Alain Wohl, M.D.

The Curious Case of M184V, Part 1

Paul Sax, M.D., writes that for those seeing HIV patients on a regular basis, the question "what should be done after M184V?" is both quite relevant clinically and, surprisingly, not readily answerable from the literature.

By Paul E. Sax, M.D. for NEJM Journal Watch